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Despite ongoing efforts, sub-Saharan Africa faces a higher cervical cancer burden than
anywhere else in the world. Besides HPV infection, definitive factors of cervical cancer
are still unclear. Particular states of the cervicovaginal microbiota and viral infections are
associated with increased cervical cancer risk. Notably, HIV infection, which is prevalent
in sub-Saharan Africa, greatly increases risk of cervicovaginal dysbiosis and cervical
cancer. To better understand and address cervical cancer in sub-Saharan Africa, a better
knowledge of the regional cervicovaginal microbiome is required This review establishes
current knowledge of HPV, HIV, cervicovaginal infections, and the cervicovaginal
microbiota in sub-Saharan Africa. Because population statistics are not available for the
region, estimates are derived from smaller cohort studies. Microbiota associated with
cervical inflammation have been found to be especially prevalent in sub-Saharan Africa,
and to associate with increased cervical cancer risk. In addition to high prevalence and
diversity of HIV and HPV, intracellular bacterial infections such as Chlamydia, Gonorrhea,
and Mycoplasma hominis are much more common than in regions with a low burden
of cervical cancer. This suggests the prevalence of cervical cancer in sub-Saharan
Africa may be partially attributed to increased cervical inflammation resulting from higher
likelihood of cervical infection and/or microbial dysbiosis.
Keywords: HPV, HIV, cervical cancer, microbiome, sub-saharan Africa
INTRODUCTION
In sub-Saharan Africa, cervical cancer risk is far greater than in developed countries. Human
Papillomavirus (HPV) is a major health concern worldwide, contributing to an estimated 4.8%
of all cancers (Forman et al., 2012). This percentage drastically increases in less developed regions
of the world, with HPV attributing to 14.2% of all cancers in sub-Saharan Africa (Forman et al.,
2012). It is well-established that HPV is the causative agent of cervical cancer (De Vuyst et al.,
2013). In 2013, 485,000 women were diagnosed with cervical cancer, and 236,000 deaths were
attributed to cervical cancer. It is estimated 1 in 70 women worldwide will develop cervical cancer
before reaching 79 years of age (De Vuyst et al., 2013; Fitzmaurice et al., 2015). Cervical cancer
disproportionately affects sub-Saharan Africa, where 9% of the world’s female population accounts
for 14% of the world’s incident cervical cancer and 18% of cervical cancer related deaths (De
Vuyst et al., 2013). This results in a cervical cancer mortality risk of 2.7%, about 70% higher than
the second highest region: South-Central Asia (De Vuyst et al., 2013). In 2013, cervical cancer
Klein et al. The Cervical Microbiome and Cancer
was the most common cause of cancer death in women in 46
of 54 sub-Saharan African countries (85%) (Fitzmaurice et al.,
2015). Only 5 countries outside of sub-Saharan Africa count
cervical cancer as the most common cause of cancer death in
women. Despite current efforts against cervical cancer in sub-
Saharan Africa, it is estimated the number of cervical cancer
cases will continue to rise, highlighting the need to bring sub-
Saharan Africa up to modern standards for HPV treatment and
prevention, and to understand the factors contributing to cervical
cancer in the region (Williamson, 2015).
Sub-Saharan Africa faces many unique issues regarding
cervical cancer. Screening and prevention practices, sociocultural
aspects, HPV genotype prevalence, HIV prevalence, HIV
treatment, sexually transmitted infections (STIs), and the
composition of the cervicovaginal microbiome are all important
factors, which differ in sub-Saharan Africa compared to more
developed regions. While some of these factors have been
correlated with increased cervical cancer incidence, it is unclear
how or if they contribute to HPV pathogenesis.
Screening is the key to early detection and treatment of
cervical cancer and identifying at-risk populations. Cervical
cancer rates in developed countries with screening and treatment
programs, have cervical cancer rates below 10 per 100,000
women. In The USA, coverage of these screening programs
within a 48 month period is 94% of women ages 25 to 29 years,
decreasing at older ages to 69% at 45 to 49 years and 55%
at 60 to 64 years (Cuzick et al., 2014). In countries without
screening programs, cervical cancer rates are significantly higher
(Fitzmaurice et al., 2015). In sub-Saharan Africa, screening
methods and their efficiency vary significantly. Because of this,
coverage is difficult to estimate and largely based on speculation.
The most common cervical cancer screening method in sub-
Saharan Africa is visual inspection with acetic acid (VIA) rather
than the pap smear, the preferred method in developed countries.
VIA is cost effective, but is known to be less specific since
it depends on visual recognition of lesions, whereas the pap
smear identifies abnormalities at the cellular level (1999). The
major factor contributing to the high incidence of cervical cancer
in sub-Saharan Africa is the lack of reliable cervical cytology
screening. Historically, introduction of population screening
programs has reduced cervical cancer incidence by 25–77%
(Gustafsson et al., 1997). Establishing better screening programs
is a necessary step toward reducing the burden of cervical
cancer in sub-Saharan Africa, however this alone is not enough
to address the issue. Ignoring the contribution of current
screening efforts in sub-Saharan Africa, even the most drastic
decrease in cervical cancer after implementation of population
screening seen historically (77%) would not bring cervical cancer
rates as low as those in developed countries with population
screening. This emphasizes the importance of understanding
and addressing what other factors in sub-Saharan Africa are
contributing to cervical cancer.
Abbreviations: NILM, Normal for intraepithelial malignancy; HPV, human
papillomavirus; HIV, human immunodeficiency virus; ART, antiretroviral
therapy; CST, community state types; STI, sexually transmitted infection;
VIA, visual inspection with acetic acid; PID, pelvic inflammatory disease; BV,
bacterial vaginosis.
Besides screening, most factors correlated with developing
cervical cancer relate to the cervical immune microenvironment.
Recent research into the cervicovaginal microbiome has
uncovered intricate relationships between the bacterial
microbiota, HPV, HIV, and cervical cancer (Godoy-Vitorino
et al., 2018; Huang et al., 2018; Klein et al., 2019). These
relationships suggest that certain cervicovaginal microbes, or the
microenvironment created by certain microbes, are cofactors
of cervical cancer progression. HIV is a well-studied factor in
sub-Saharan Africa, which influences the cervical microbiota.
Cervical cancer is classified as an AIDS-defining cancer due to
greatly increased risk among HIV positive individuals with low T
cell count. Despite extensive study of the prevalence and impact
of HIV in sub-Saharan Africa, the exact mechanism by which
HIV infection contributes to HPV driven cervical cancer remains
unclear. A better understanding of other correlated factors will
help clarify the mechanisms which drive cervical cancer, and
address how to bring sub-Saharan Africa in line with other
regions. STI screening of genital tract infections like chlamydia
and gonorrhea has found they are much more prevalent in sub-
Saharan Africa, while, metagenomic studies of the cervicovaginal
microbiome have shown significant differences between the
commensal and non-commensal components of sub-Saharan
African microbiomes when compared with low cervical cancer
risk areas. Considering such infections have been associated
with pre-cancerous lesions, it is likely these differences, in part,
account for sub-Saharan Africa’s increased cervical cancer risk
(Onywera et al., 2019).
Defining differences in cervical microbiota by geographic
location, HIV status, and cervical cytology using compiled
published data is difficult due to major differences in cohort
makeup, cohort size, sampling and sequencing techniques, and
other issues. The cervical microbiota varies greatly between
individuals. Factors such as age, race, menstrual phase, and
lifestyle have all been shown to affect the microbiome.
Controlling for such a large number of factors is difficult,
which has hindered the discovery of definitive microbiota.
Furthermore, the microbiota of the cervix has been shown to be
significantly different than that of the vagina, thus studies which
sample the cervicovaginal microbiome do not best represent
the microenvironment at the site of cervical transformation
(Koedooder et al., 2019). For these reasons, the results of
studies are considered individually in this review, so that each
speaks only for the niche represented by its cohort. To better
understand and address the relationship between HPV, HIV,
cervical microbiota, and increased cervical cancer risk, a better
understanding of the unique sub-Saharan African environment
is needed. Here, we discuss current knowledge in each of these
areas, highlighting factors especially prevalent in sub-Saharan
Africa which may drive HPV-dependent cervical cancer.
HPV GENOTYPES
The HPV family includes more than 200 genotypes, over 45 of
which are known to infect the anogenital region. The regional
prevalence and oncogenic potential of HPV genotypes varies
significantly. Fifteen anogenital HPVs are classified as high-
risk for development of cervical cancer (Guan et al., 2012).
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Among these, HPV16 and 18 are the predominant oncogenic
genotypes, causing approximately 70% of cervical cancer cases
globally (Ogembo et al., 2015). The relative oncogenic potential
of HPV 16 and 18 has been shown to be markedly higher
than that of other genotypes, followed by 45, 69, 58, 31, 33,
34, 67, 39, 59, 73, and 52 by decreasing oncogenic potential
(Bernard et al., 2013). Of the global HPV burden, 22.5% of HPV
infections are estimated to be produced by HPV-16, however, a
significant inverse correlation has been observed between overall
HPV prevalence and the contribution of HPV-16, with the
lowest HPV16 proportions in the regions with the highest HPV
prevalence (Bruni et al., 2010). Not surprisingly, sub-Saharan
Africa has been shown to have the lowest HPV-16 contribution
to total HPV infections in women with normal cervical cytology
when compared to other regions, with estimates of 13.7, 11.3, and
11.1% for Southern, Eastern, and Western Africa, respectively
(Bruni et al., 2010). This correlation is even more pronounced
in cervical cancer, where HPV16 and 18 are less frequent in sub-
Saharan Africa than in the rest of the world (49.4 vs. 62.6%),
while HPV18 and HPV 45 are two times more frequent (19.3
vs. 9.4% and 10.3 vs. 5.6%) (Ndiaye et al., 2012). After HPV16
and 18, the most prevalent genital HPV genotypes vary between
sub-Saharan Africa countries. Overall, HPV 52, 35, 58, 33, 31,
45, 53, and 51 are the most prominent non-16/18 genotypes
in sub-Saharan Africa (Forman et al., 2012; Abate et al., 2013;
Olesen et al., 2013; Adler and Wallace, 2014; Boumba et al.,
2014, 2015; McDonald et al., 2014; Mihret et al., 2014; Bateman
et al., 2015; Lebelo et al., 2015; Okonko and Ofoedu, 2015;
Padalko et al., 2015; Pirek et al., 2015; van Aardt et al., 2015).
When comparing prevalence with high-income regions, HPV
52, 58, 33, and 45 stand out as especially prevalent in sub-
Saharan Africa (Bruni et al., 2017). Because these HPV genotypes
are only common in Sub-Saharan Africa, they have not been
as well-researched as globally prevalent HPVs such as 16 and
18. Potential differences in pathogenesis in such genotypes may
contribute to increased cervical cancer in Sub-Saharan Africa,
where a larger percentage of cervical cancer cases are attributed
to non-HPV16/18 genotypes.
Accurate detection and identification of HPV genotypes
depends upon the genotyping method used. Most large studies
use one of several established genotyping assays, however
more recent studies using sequencing-based identification
of HPV genotypes have found that genotyping assays may
only detect as little as 49% of those able to be detected with
sequencing (Ndiaye et al., 2012). The bias introduced by
genotyping assays may downplay the significance of certain
HPV genotypes in Sub-Saharan Africa, especially those
which have not been well-researched, such as HPV 34, 67,
69, and 73. Additionally, the extensive sequence variation
within HPV genotypes, which has been demonstrated to be
especially severe in Sub-Saharan Africa, is not accounted for by
genotyping assays as it is in sequenced-based approaches,
and may be of clinical importance. Sequence variation
of HPV may also contribute to reduced efficacy of HPV
vaccination in Sub-Saharan Africa, while increased genotypic
diversity of HPV almost certainly does. A more complete
understanding of the microbiome/HPV interactions is
necessary before an effective microbiome-based intervention can
be developed.
Concurrent cervical infection with multiple HPV genotypes
is common in Sub-Saharan Africa, however it is not clear
if this represents a specific mechanism driving pathogenesis.
Data from developed regions suggests multiple infection with
HPV decreases in cervical cancer cases, however studies in
Sub-Saharan Africa suggest coinfection is more prevalent in
cervical cancer and may exacerbate HPV pathogenesis. A study
of South African women with cervical cancer found that 65%
were coinfected with at least two HPV genotypes (Lebelo et al.,
2015). Of the coinfected cervical cancer cases, 90.4% included
HPV16, suggesting infection with other HPV genotypes may
contribute to HPV16 driven cervical cancer. Similar results were
found in a study of women in the Democratic Republic of Congo
(Boumba et al., 2014). Further work has shown higher HPV16
viral loads in 70.3% of HPV16 coinfected samples (Lebelo et al.,
2015). In a separate study, Cameroonian women with normal
cervical cytology and multiple HPV infections were found to be
about 10% more likely to develop cervical lesions within a year
when compared to women infected with a single HPV type (Pirek
et al., 2015). These results suggest a synergistic effect driving HPV
replication and cervical cancer pathogenesis in cases of multiple
HPV infection.
In contrast, other publications have suggested HPV16 may
be more sensitive to attack from other genotypes, and thus may
be at higher risk of competition when there is more immune
suppression (Menon et al., 2016). Ameta-study examining global
HPV prevalence found that multiple HPV infections were, on
average, 6% more common in women with normal cytology than
in those with cervical cancer (Bernard et al., 2013). Sub-Saharan
Africa was the least represented region by studies included in
this analysis, allowing for the possibility that synergistic effects in
cases of multiple infection are primarily found in the genotypes
most prevalent in Sub-Saharan Africa. Further research focusing
on the long-term oncogenic potential of different combinations
of HPV genotypes, is necessary.
HIV
HIV is the best studied co-factor to cervical cancer and
has been strongly linked to severe HPV pathogenesis. The
association between severe HIV pathogenesis and cervical cancer
has classified cervical cancer as an “AIDS-defining cancer.” In
addition to increasing cervical cancer risk, evidence suggests that
highHIV prevalence also contributes to increased prevalence and
circulation of HPV (Williamson, 2015). Similarly, the widespread
prevalence of multiple HPV infections has been shown to
contribute to the spread of HIV by increasing susceptibility
of HIV acquisition. Multiple studies have shown that immune
response to HPV increases HIV-susceptible cells in both male
and female genital tracts, increasing the opportunity for an initial
infection to occur based on the local immune microenvironment
(Averbach et al., 2010; Tobian et al., 2013; Williamson, 2015).
The regional relationship between HIV prevalence and cervical
cancer is shown in Figure 1, which demonstrates associations
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FIGURE 1 | Comparison of cervical cancer incidence and HIV Prevalence by country. Each country is colored by cervical cancer incidence per 100,000 women, as
described in the bottom left, based on data from GLOBOCAN 2012. Circles within each country’s borders are colored by HIV prevalence, as described in the bottom
left, based on data from UNAIDS (2016). Differences in the size of circles within countries is only for visibility and does not signify anything meaningful. Countries
without HIV prevalence circles did not have such data available. Map produced by IARC.
between the two globally, highlighting the exceptionally high
rates seen in Sub-Saharan Africa.
Risk factors and predictors of cervical cancer are also
increased in HIV+ individuals. HPV infection, abnormal Pap
smears, and high-grade lesions are significantly more common in
HIV+ women (Adler and Wallace, 2014; Salazar et al., 2015). In
addition to the increased rate of productive HPV infection, HIV
is associated with a higher risk of progression from subclinical to
clinical HPV disease (Williamson, 2015). Higher HPV viral loads
are associated with increased risk of abnormal cervical cytology,
and are seen among those co-infected with HIV, indicating this
may in part be due to an undefined mechanism by which HIV
infection influences HPV viral replication factors (Depuydt et al.,
2012; Wang et al., 2013; Hanisch et al., 2014; Mbulawa et al.,
2014). A likely factor in this is a decrease in T-cell surveillance
controlling HPV replication with decreasing CD4+ cell count
as HIV progresses. Multiple studies have shown an increase in
HPV detection, squamous intraepithelial lesions, and cervical
intraepithelial neoplasia in individuals with AIDS (less than 200
CD4+ cells per µl serum) (Hanisch et al., 2013; Ezechi et al.,
2014; Memiah et al., 2015; Menon et al., 2016). Identifying
which aspects of the local and systemic effects of HIV infection
contribute to progression from chronic HPV infection to cervical
cancer is crucial to understanding the burden of cervical cancer
in Sub-Saharan Africa. Current knowledge suggests effects on the
cervical immune microenvironment may be key in this process.
In HIV+ populations, there is a shift in prevalence of HPV
genotypes, favoring high-risk HPVs (Ezechi et al., 2014). The
reasoning for greater prevalence of certain HPV genotypes
in HIV+ individuals is not currently well-understood. The
influence of HIV may help explain why coinfection of multiple
HPV genotypes is associated with cervical cancer in sub-Saharan
Africa, but not elsewhere. Studies from several Sub-Saharan
African countries have identified a greater number of multiple
HPV infections among HIV-positive women (Akarolo-Anthony
et al., 2013; Maranga et al., 2013; Adler and Wallace, 2014;
McDonald et al., 2014; van Aardt et al., 2015). A study of
South African females with cervical cancer found multiple HPV
infections in 8% of HIV- women and 27% of HIV+ women
(van Aardt et al., 2015). In a study of South African adolescent
females, the prevalence of multiple infections was found to be
much higher in both HIV positive and negative individuals, with
22% percent prevalence in HIV- and 68.6% in HIV+ (Adler
and Wallace, 2014). Only 18.8% of all adolescents in this study
had an abnormal pap smear, and none of them were diagnosed
with cervical cancer. This supports the idea that exposure to
many HPV types occurs early after sexual debut, with certain
genotypes becoming dominant by the time HPV pathogenesis
reaches cervical cancer. Potentially, infection with “accessory”
HPV genotypes contributes to the early pathogenesis of a primary
high-risk HPV either directly or through manipulation of the
immune microenvironment, leading to increased replication and
eventual faster or more frequent development of cervical cancer.
These “accessory” HPV infections may then be cleared by a
competent immune response, which may explain why multiple
infection decreases in HIV- cervical cancer cases, but not in
HIV+. Based on current evidence, it is yet unclear whether
early multiple HPV infections expedite progression to cervical
cancer. A short-term longitudinal study (16 months) was unable
to find any additive or synergistic effect of multiple infection on
development of cervical lesions, noting that increased frequency
of cervical lesions was associated with infection of a single high-
risk HPV. Cervical cancer development occurs over a period of
decades however; looking at such a narrow time frame means
these results may be a consequence of only observing cytological
effects in infections in which a high-risk HPV was already
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established and progressing toward cervical cancer, not early
interactions which eventually contribute to lesions (Salazar et al.,
2015). Further study focusing on interactions and outcomes in
HPV coinfection, especially among young HIV+ women who
have not yet developed cervical dysplasia, is desirable to clarify
this relationship.
When available, treatment for individuals infected by HIV
in sub-Saharan Africa is primarily antiretroviral therapy (ART).
Unlike high-income regions, most HIV infected sub-Saharan
African individuals go without treatment. ART coverage of HIV
infected individuals across sub-Saharan Africa is estimated to
be 40.2% or less (UNAIDS, 2016). Studies examining the effects
of ART on HPV pathogenesis have had mixed results. While
previous studies suggest ART has no significant effect on HPV
genotype detection, more recent studies suggest modern ART
reduces the prevalence of high-risk HPV’s in HIV infected
women (Palefsky, 2003; Ezechi et al., 2014; Zeier et al., 2015).
This reduction in high-risk HPV prevalence grows with duration
of ART use. Besides a reduction of HIV, the effects of ART
on cervical microbiota are currently unknown, but may be
significant, as several studies have found that ART affects the gut
microbiota. ART does not appear to have a significant effect on
cervical lesions and tumor development, and only minor effects
on limiting progression of lesions and preventing recurrence
(Ahdieh-Grant et al., 2004; Paramsothy et al., 2009; Dryden-
Peterson et al., 2015; Memiah et al., 2015). A study of Kenyan
women found that the spread of ART has been accompanied
with a decrease in age-specific cancer risk, however an increase
in the number of HPV cancers, which is attributed to an aging
HIV+ population rather than to any effect of ART (Memiah et al.,
2015). Compared to the risk reduction after ART seen in other
AIDS-defining cancers like Kaposi’s sarcoma and non-Hodgkin’s
lymphoma, the risk of cervical cancer is not significantly affected,
and recurrence rates remain high with or without treatment
(Foulot et al., 2008; Mungo et al., 2013; Russomano et al.,
2013; Cobucci et al., 2015). This suggests that HPV depends on
immunological status of the host such that ART is only able to
indirectly affect HPV pathogenesis, potentially through an effect
on circulatory CD4+ cell count and microbiota composition.
NON-VIRAL MICROBIOTA
Several studies have proposed that the cervicovaginal microbiota
is a co-factor of the development of cervical lesions (Guijon
et al., 1992; Kyrgiou et al., 2016; Mitra et al., 2016). The
precise mechanism, and the microbes responsible have not
been identified, but several common STIs have been associated
with cervical cancer individually. Health of the lower female
reproductive tract, and its ability to defend against dysbiosis
and infection, is directly related to the microbiota present.
Its defense mechanisms include antimicrobial peptides, a
microbiome dominated by Lactobacilli, and a pH of <4.5.
An imbalance in these defenses can result in physiochemical
changes, which produce histological alterations of the vaginal
mucosa and cervical epithelium (Audirac-Chalifour et al., 2016).
Communal differences in the cervical microbiome between
sub-Saharan Africa and developed regions have not been
well-established, however the prevalence and incidence of
pathogenic cervicovaginal microbiota is much higher in sub-
Saharan Africa. Among factors associated with preventing or
developing cervical cancer, cervicovaginal pathogens are second
only to HPV vaccine coverage when comparing differential rates
in sub-Saharan Africa and North America (Table 1). Nearly
all studies of the cervicovaginal microbiome in sub-Saharan
Africa to date have used sequencing of the ribosomal RNA 16s
amplicon, which only includes bacteria. Because of this, little
is known of the virome or other non-bacterial members of
the microbiome outside of targeted screening. Whole genome
sequencing (WGS) allows characterization of the microbiome
in its entirety and has been shown to be more accurate at the
detection of bacterial species and diversity than 16s (Ranjan
et al., 2016). RNA sequencing (RNASeq) is another powerful
approach to characterize gene expression, which is now being
used in microbiome studies. Large scale metagenomic studies
of sub-Saharan African populations using WGS is needed to
more fully characterize the microbiome and address potential
bias introduced by 16s sequencing. These newer methods
are likely to improve our understanding of these complex
microbial networks.
Non-commensal Microbiota
Chronic inflammation of the cervix is closely associated with
developing cervical cancer (Giraud et al., 1998; Skapinyecz et al.,
2003; Ilhan et al., 2019). Cervicitis can result from several
different conditions, which often are attributed to infection with
non-commensal microbes. Pelvic inflammatory disease (PID)
in women usually results from bacterial infection of the cervix
ascending to the uterus and oviducts, wherein certain bacteria
express antigens which induce a chronic inflammatory state.
The association observed between PID and cervical cancer is
thought to be due to development of a microbiome rich in
inflammation-inducing bacteria at the cervix, causing cervicitis.
Not surprisingly, PID is more prevalent in HIV-infected women
than uninfected (Dehon et al., 2016). The overall prevalence
of PID is difficult to define in sub-Saharan Africa, however
diagnosis of PID is more than twice as likely to be attributed to
a bacterial infection when compared to rates in the developed
world (Ross, 2008). This suggests that bacterial infections more
often contribute to HPV pathogenesis in Sub-Saharan Africa.
Bacterial vaginosis (BV) is a dysbiosis of cervicovaginal
bacteria which, like PID, is associated with cervicitis (Lehtinen
et al., 2011; Ogembo et al., 2015). BV alters the cervicovaginal
microenvironment, which may increase cervical dysplasia as
a result of anaerobic infection producing nitrosamines, which
cause cervical inflammation (Lazenby et al., 2014). The
microenvironment created by BV has also been identified as
a cofactor in the persistence of HPV infection (Gillet et al.,
2011; Clarke et al., 2012; Guo et al., 2012; Vriend et al., 2015).
Several of the causal bacteria of BV are associated with cervical
lesions and/or inflammation. The most common causes of
BV are: Gardnerella vaginalis, Atopobium vaginae, Mobiluncus
curtisii, Mobiluncus mulieris, Megasphaera type 1, Megasphaera
type 2, Sneathia sanguinegens,Mycoplasma hominis,Mycoplasma
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TABLE 1 | Comparison of factors which may influence cervical cancer in sub-Saharan Africa and North America (Koumans et al., 2007; WHO, 2012; Ferlay et al., 2013;
CDC, 2014; CDC STD Surveillance, 2015; UN World Fertility Patterns, 2015; WHO Report on the Global Tobacco Epidemic, 2015; Bautista et al., 2016; UNAIDS Global
AIDS Update, 2016; UNAIDS Database, 2017; Gonorrhea-CDC Fact Sheet, 2019).
North America Sub-Saharan Africa % Difference in
sub-Saharan Africa
Fold difference
HPV Vaccine Coveragea 35.6% 1.2% 3% 29.7–
Neisseria gonorrhoeae Incidence 259.3 5,500 2,121% 21.2+
HIV Prevalence 0.3% 4.38% 1,460% 14.6+
Smoking Prevalenceb 15.67% 2.3% 15% 6.8–
Trichomonas vaginalis Prevalencec 3.1% 20.2% 652% 6.5+
cervical cancer Incidenced 6.6 35.18 533% 5.3+
Chlamydia trachomatis Incidence 456.1 2160 474% 4.7+
Proportion of Adenocarcinoma cervical cancer 18% 5.5% 30.6% 3.3–
Fertilitye 1.9 4.7 247% 2.8+
HPV Prevalence (NILM) 13.8% 22.9% 166% 1.7+
Anti-Retroviral Therapy Coverage 59% 40.2% 68% 1.5-
Bacterial Vaginosis 29.2% 41.4% 142% 1.4+
HPV 16/18 Prevalence in cervical cancer 71.4% 62.8% 88% 1.1–
aWomen aged 10–20, full-course.
b In surveyed females 15+.
cWomen ages 14+.
dAge standardized rate per 100 k women per year.
eChildren per woman.
genitalium, Ureaplasma urealyticum, Bacteriodes fragilis, and
bacterial-vaginosis-associated-bacteria (BVAB) 1-3 (Signat et al.,
2011; Audirac-Chalifour et al., 2016). Comparative genomic
analysis has shown that the shift in microbial diversity as a
result of BV is more pronounced in women infected with HIV,
suggesting BV is more severe in this population and thus more
likely to drive HPV pathogenesis (Spear et al., 2008). In sub-
Saharan Africa, BV prevalence is estimated to range from 20 to
50% in reproductive aged women, making it the most common
cause of cervicovaginal dysbiosis. This prevalence suggests BV,
or the cervical microenvironment created by BV, could be a
major contributor to increased malignant HPV pathogenesis in
the region, especially among HIV+ women (Msuya et al., 2002;
Lewis, 2011; Swanepoel et al., 2013). Further study is necessary to
determine if general inflammation caused by conditions like BV
and PID is sufficient to promote HPV pathogenesis, or if specific
microbes which contribute to the diseases are responsible.
STIs also alter the cervicovaginal microenvironment. Several
sexually transmitted microbes have been associated with
cervicitis and persistence of HPV infection (Gillet et al., 2011;
Lehtinen et al., 2011; Clarke et al., 2012; Guo et al., 2012;
Ogembo et al., 2015; Vriend et al., 2015). Among these, Neisseria
gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis, and
Syphilis are particularly common in sub-Saharan Africa. Sub-
Saharan Africa accounts for a disproportionate 20, 9.9, 31.7, and
32.2% of worldwide cases respectively, resulting in significantly
higher incidence than in high-income regions (Table 1) (Guijon
et al., 1992; Lewis, 2011; Rodriguez-Cerdeira et al., 2012;
Swanepoel et al., 2013). This issue is exacerbated by the large
HIV+, immunocompromised population, which is more readily
infected. Screenings of sub-Saharan African women estimate 70–
80% of those infected with discharge-causing infections remain
asymptomatic (Sylverken et al., 2016; Barnabas et al., 2018). This
contributes to increased transmission, but also allows infections
to persist for longer before treatment, meaning persistence of
a cervical microenvironment conducive to cervical lesions and
HPV persistence. Less screened infectious microbes such as
Mycoplasma spp., Ureaplasma spp., and Leptotrichia amnionii
have been shown to be involved in cervicitis in HIV+ women
(Linhares et al., 2000; Dehon et al., 2016; Mitra et al., 2016).
Mycoplasma infection has also been directly associated with pre-
cancerous cervical lesions (Klein et al., 2019). When screening
for STIs,Mycoplasma genitalium is more often included, however
Mycoplasma hominis, which is similar to M. genitalium in
pathogenesis, is rarely screened for. Because of this, a good
estimate of Mycoplasma prevalence in sub-Saharan Africa is not
well-established. In sub-Saharan African cohort studies which
include M. hominis detection, prevalence of M. hominis ranges
from 17 to 67.5%, far exceeding M. genitalium (Agbakoba et al.,
2007; Redelinghuys et al., 2013; Kouegnigan Rerambiah et al.,
2015; Sylverken et al., 2016). This is significantly higher than what
has been shown in North America and may be due to the HIV+
population acting as a reservoir forM. hominis infection (Djigma
et al., 2011).
Commensal Microbiota
The cervicovaginal microbiome has been shown to most often
fall into one of seven general community state types (CSTs)
(Salas and Chang, 2014; Mitra et al., 2016). These CSTs are
characterized by the relative abundance of various species
of Lactobacillus and anaerobic bacteria and are separated
into healthy and dysbiotic groups. The healthy CSTs are all
Lactobacillus dominated; type 1 is dominated by L. crispatus,
type 2 by L. gasseri, type 3 by L. iners, and type 5 by L. jensenii.
Common dysbiotic CSTs are characterized by an abundance of
anaerobic bacteria; type 6 is dominated by Gardnerella vaginalis,
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FIGURE 2 | Model for the cervical microbial and immune microenvironment driving cervical cancer. Microbial dysbiosis and infection at the cervical epithelium results
in increased local expression of inflammatory and wound healing cytokines (IL1 and IL6). Chronic expression of these cytokines can result in increased genetic
instability and reduced tumor-suppressor protein function in infected cells. These conditions increase HPV replication, while also increasing risk of mutation and
integration of the HPV genome. Thus, the cervical microbiota can increase the risk for events necessary in the transformation of cells by HPV.
type 4 is characterized by a high abundance of anaerobic bacteria
and low abundance of Lactobacillus species, and type 7 is
characterized by high abundance of both Gardnerella vaginalis
and Lactobacillus species. These cervicovaginal CSTs have been
previously associated with significantly different prevalences of
infecting HPV genotypes (Brotman et al., 2014; Mitra et al., 2015;
Dareng et al., 2016; Reimers et al., 2016). L. crispatus dominated
microbiomes (type 1) are considered to be the most protective
against HPV and HIV, and have been shown to be significantly
less likely to have HIV, HSV-2, any HPV, or high-risk HPV
than other CSTs (Borgdorff et al., 2014). L. crispatus produces
lactic acid, antimicrobial compounds, and inhibits inflammation
(Graver and Wade, 2011; Hickey et al., 2012; Rose et al., 2012;
Aldunate et al., 2013; Petrova et al., 2013). These represent
likely mechanisms by which L. crispatus, and potentially other
microbes, are able to influence HPV infection and progression
of HPV-associated diseases. A study of Rawandan women found
that women with the L. crispatus dominated CST had the lowest
prevalence of HIV/STIs, with a slight increase in the L. iners
dominated CST, and a significant increase in the dysbiotic CSTs
(types 4, 6, and 7) (Borgdorff et al., 2014). Similar results have
been found in studies of Nigerian and South African women,
supporting an association between HPV pathogenesis and
decreased abundance of Lactobacillus spp. (Dareng et al., 2016;
Onywera et al., 2019). L. crispatus is much less abundant in sub-
Saharan Africa than in high-income regions (Jespers et al., 2015).
Instead, L. iners is the most abundant “protective” cervicovaginal
microbe, especially in HIV+ women without dysbiosis. L. iners
dominated microbiomes have been shown to be less protective
against cervicovaginal infections, and closer to dysbiotic CST
rates of HPV infection and cervical dysplasia (Norenhag et al.,
2020). This suggests that differences in commensal microbiota
in sub-Saharan Africa are also contributing to the prevalence
and transmission of cervicovaginal infection and dysbiosis in
the region.
CONCLUSION
Cervical cancer, a preventable and treatable cancer, remains the
cancer with the highest incidence in women in 27 countries,
and the leading cause of cancer death in women in 45
countries, most of which are in sub-Saharan Africa. Efforts to
determine the most cost-effective strategies to reduce cervical
cancer burden through human papillomavirus vaccination and
screening are ongoing and will hopefully lead to a continued
decrease in cervical cancer incidence in the most affected
areas of the world. However, it is expected that the number
of women with cervical cancer in sub-Saharan Africa will
increase as more women get access to HIV therapy, increasing
the life expectancy of HIV+ women (Williamson, 2015).
There is therefore an urgent need to roll out better cervical
screening programs. To accomplish this, a better understanding
of the region’s unique factors contributing to cervical cancer
is necessary to improve identification and treatment of at-
risk individuals before the onset of disease. Current screening
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and vaccination in Sub-Saharan Africa is sparse, irregular,
and does not consider factors beyond HIV and cervical
lesion status. In considering the factors contributing to Sub-
Saharan Africa’s disproportionate burden of cervical cancer, the
disparity between HPV prevalence, HPV genotype prevalence,
and sociocultural factors in Sub-Saharan Africa and high-income
regions is much less than the disparity seen in vaccination and
cervicovaginal infection and dysbiosis, suggesting that disruption
of the cervicovaginal microbiome may be the most significant
factor and predictor of cervical cancer in Sub-Saharan Africa.
Research up to this point suggests that latent, basal layer
infections of HPV’s are activated when sensing the host is
immunocompromised, leading to increased HPV replication and
development of abnormal cytology. HIV and dysbiosis of the
cervicovaginal microbiome are the most common factors in
sub-Saharan Africa able to activate HPV via effects on the cervical
immune microenvironment. ART may help reduce these effects
by restoring immune competence, however it does not return
activated HPVs to full latency. Transition to cervical cancer
is associated with a single HPV genotype becoming dominant,
however data suggests coinfection with multiple HPV genotypes
or other cervical pathogens plays an important role early on,
potentially contributing to the early pathogenesis of a primary
high-risk HPV either directly or through manipulation of the
immune microenvironment, leading to increased replication and
eventual faster or more frequent development of cervical cancer.
This process is likely mediated by expression of inflammatory
and wound healing cytokines such as IL1, IL6, TNFα, and
IFNγ, leading to cell stress and genetic instability, increasing the
risk of mutation or integration of the episomal HPV genome
(Figure 2). These infections are likely cleared by a competent
immune response, which may explain why multiple infection
decreases in HIV- cervical cancer cases, but not in HIV+,
immunocompromised individuals. A better understanding of
the early events influencing HPV control and persistence in
the genital tract is needed to test this theory. In Sub-Saharan
Africa particularly, further research on the impact of HIV on
these early events is desirable. Identification of the microbial risk
factors for development of cervical cancer will allow for improved
identification of those at elevated risk, while improving design
and application of primary and secondary preventative treatment
and screening.
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